Chronic Heart Failure - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 156 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Heart Failure - Pipeline Review, H2 2016, provides an overview of the Chronic Heart Failure (Cardiovascular) pipeline landscape.

Chronic heart failure is a serious condition caused by the heart failing to pump enough blood around the body at the right pressure. The symptoms develop gradually. Common symptoms are cough, fatigue, weakness, faintness, loss of appetite; need to urinate at night, shortness of breath, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. Risk factors that contribute to heart failure are high blood pressure, coronary artery disease, heart attack, diabetes and alcohol use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Heart Failure - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Heart Failure (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Heart Failure (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 9, 11, 2 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Chronic Heart Failure.

Chronic Heart Failure (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Heart Failure (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Chronic Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Heart Failure (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Heart Failure (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Heart Failure (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Chronic Heart Failure Overview 10
Therapeutics Development 11
Pipeline Products for Chronic Heart Failure - Overview 11
Pipeline Products for Chronic Heart Failure - Comparative Analysis 12
Chronic Heart Failure - Therapeutics under Development by Companies 13
Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 15
Chronic Heart Failure - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Chronic Heart Failure - Products under Development by Companies 19
Chronic Heart Failure - Products under Investigation by Universities/Institutes 20
Chronic Heart Failure - Companies Involved in Therapeutics Development 21
Amgen Inc. 21
AnGes MG, Inc. 22
AstraZeneca Plc 23
Bayer AG 24
Capricor Therapeutics, Inc. 25
Celyad SA 26
Juventas Therapeutics, Inc. 27
Laboratoires Pierre Fabre SA 28
Les Laboratoires Servier SAS 29
Mast Therapeutics, Inc. 30
Mesoblast Limited 31
Novartis AG 32
Pfizer Inc. 33
scPharmaceuticals Inc 34
Stemedica Cell Technologies, Inc. 35
Theravance Biopharma, Inc. 36
Vichem Chemie Research Ltd. 37
Zensun (Shanghai) Sci & Tech Co., Ltd. 38
Chronic Heart Failure - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(sacubitril + valsartan) - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
beperminogene perplasmid - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
C3BSCQR-1 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
cenderitide - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
CLR-325 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
dapagliflozin propanediol - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
F-373280 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
furosemide - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
ivabradine hydrochloride - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
JVS-100 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
L-2286 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
MPC-150IM - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
neladenoson bialanate - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Neucardin - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
omecamtiv mecarbil MR - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
rivaroxaban - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
S-38844 - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
serelaxin - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
sildenafil citrate - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
Small Molecules for Chronic Heart Failure - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 132
Product Description 132
Mechanism Of Action 132
R&D Progress 132
TD-1439 - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
vepoloxamer - Drug Profile 134
Product Description 134
Mechanism Of Action 134
R&D Progress 134
vericiguat - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
Chronic Heart Failure - Dormant Projects 143
Chronic Heart Failure - Discontinued Products 145
Chronic Heart Failure - Product Development Milestones 146
Featured News & Press Releases 146
Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients 146
Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting 147
Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure 148
Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting 148
Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development 149
Aug 28, 2016: CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications 149
Jul 01, 2016: Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations 151
Jun 28, 2016: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy 152
Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology 153
Jun 14, 2016: Mesoblast Provides Update On Global Heart Failure Program 154
May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress 155
May 23, 2016: Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure 155
May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016 156
Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition 157
Apr 26, 2016: Celyad receives certification for C-Cure non-clinical data from the European Medicines Agency 158
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160

List of Tables

Number of Products under Development for Chronic Heart Failure, H2 2016 11
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Chronic Heart Failure - Pipeline by Amgen Inc., H2 2016 21
Chronic Heart Failure - Pipeline by AnGes MG, Inc., H2 2016 22
Chronic Heart Failure - Pipeline by AstraZeneca Plc, H2 2016 23
Chronic Heart Failure - Pipeline by Bayer AG, H2 2016 24
Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016 25
Chronic Heart Failure - Pipeline by Celyad SA, H2 2016 26
Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H2 2016 27
Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 28
Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H2 2016 29
Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H2 2016 30
Chronic Heart Failure - Pipeline by Mesoblast Limited, H2 2016 31
Chronic Heart Failure - Pipeline by Novartis AG, H2 2016 32
Chronic Heart Failure - Pipeline by Pfizer Inc., H2 2016 33
Chronic Heart Failure - Pipeline by scPharmaceuticals Inc, H2 2016 34
Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 35
Chronic Heart Failure - Pipeline by Theravance Biopharma, Inc., H2 2016 36
Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H2 2016 37
Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Assessment by Combination Products, H2 2016 40
Number of Products by Stage and Target, H2 2016 42
Number of Products by Stage and Mechanism of Action, H2 2016 44
Number of Products by Stage and Route of Administration, H2 2016 46
Number of Products by Stage and Molecule Type, H2 2016 48
Chronic Heart Failure - Dormant Projects, H2 2016 143
Chronic Heart Failure - Dormant Projects (Contd..1), H2 2016 144
Chronic Heart Failure - Discontinued Products, H2 2016 145